Journal of Microbiology

The Microbiological Society of Korea (한국미생물학회)
권호 표지

Strategies Against Human Papillomavirus Infection and Cervical Cancer

  • Jung Woon-Won (MyGene Bioscience Institute, Sungok Bldg) ;
  • Chun Taehoon (Department of Microbiology and Immunology, School of Medicine, Hanyang University) ;
  • Sul Donggeun (Environmental Toxico-Genomic and Proteomic Center, College of Medicine, Korea University) ;
  • Hwang Kwang Woo (Department of Immunology, College of Pharmacy, Chung-Ang University) ;
  • Kang Hyung-Sik (School of Biological Sciences and Technology, Biotechnology Research Institute, Chonnam University) ;
  • Lee Duck Joo (Department of Family Medicine, Samsung Cheil Hospital, Sungkyunkwan University) ;
  • Han In-Kwon (MyGene Bioscience Institute, Sungok Bldg, Department of Internal Medicine, Samsung Cheil Hospital, Sungkyunkwan University)
  • Published : 2004.12.01
Download PDF
⟨ Previous Next ⟩

Abstract

Papillomaviruses infect a wide variety of animals, including humans. The human papillomavirus (HPV), in particular, is one of the most common causes of sexually transmitted disease. More than 200 types of HPV have been identified by DNA sequence data, and 85 HPV genotypes have been well char­acterized to date. HPV can infect the basal epithelial cells of the skin or inner tissue linings, and are, accordingly, categorized as either cutaneous or mucosal type. HPV is associated with a panoply of clin­ical conditions, ranging from innocuous lesions to cervical cancer. In the early 1980s, studies first reported a link between cervical cancer and genital HPV infection. Genital HPV infections are now rec­ognized to be a major risk factor in at least $95\%$ of cervical cancers. 30 different HPV genotypes have been identified as causative of sexually transmitted diseases, most of which induce lesions in the cervix, vagina, vulva, penis, and anus, as the result of sexual contact. There is also direct evidence demon­strating that at least four of these genotypes are prerequisite factors in cervical cancer. The main aim of this review was to evaluate the current literature regarding the pathovirology, diagnostics, vaccines, therapy, risk groups, and further therapeutic directions for HPV infections. In addition, we reviewed the current status of HPV infections in South Korean women, as evidenced by our data.

Keywords

References

  1. Adam, E., Z. Berkova, Z. Daxnerova, J. Icenogle, W.C. Reeves, and R.H. Kaufman. 2001. Papillomavirus detection: demographic and behavioral characteristics influencing the identification of cervical disease. Am. J. Obstet. Gynecol. 182, 257-264
  2. Allen, M., M. Kalantari, A. Ylitalo, B. Pettersson, B. Hagmar, L. Scheibenplug, B. Johansson, U. Petterson, and U. Gyllensten. 1996. HLA DQ-DR haplotype and susceptibility to cervical carcinoma: indications of increased risk for development of cervical carcinoma in individuals infected with HPV 18. Tissue Antigens 48, 32-37 https://doi.org/10.1111/j.1399-0039.1996.tb02602.x
  3. Andrei, G., R. Snoeck, J. Piette, P. Delvenne, and E. DeClercq. 1998. Antiproliferative effects of acyclic nucleoside phosphonates on human papillomavirus (HPV)-harboring cell lines compared with HPV-negative cell lines. Oncol. Res. 10, 523-531
  4. Apple, R.J., T.M. Becker, C.M. Wheeler, and H.A. Erlich. 1995. Comparison of human leukocyte antigen DR-DQ disease associations found with cervical dysplasia and invasive cervical carcinoma. J. Natl. Cancer Inst. 87, 427-436 https://doi.org/10.1093/jnci/87.6.427
  5. Baker, T.S., W.W. Newcomb, N.H. Olson, L.M. Cowsert, C. Olson, and J.C. Brown. 1991. Structures of bovine and human papillomaviruses. Analysis by cryoelectron microscopy and threedimensional image reconstruction. Biophys. J. 60, 1445-1456
  6. Bonnez, W. and R.C. Richman. 1994. Papillomaviruses, p. 1630-1640. In G.L. Mandell, J.E. Bennett, and R. Dolin R (eds.), Nandell, Douglas, and Bennetts principles and practice of infectious diseases, 5th ed. Churchill Livingston, Philadelphia, Pennsylvania
  7. Bontkes, H.J., M. Van Duin, T.D. deGruijl, M.F. Duggan-Keen, J.M. Walboomers, M.J. Stukart, R.H. Vereheijen, T.J. Helmerhorst, C.J. Meijer, R.J. Scheper, F.R. Stevens, P.A. Dyer, P. Sinnott, and P.L. Stern. 1998. HPV 16 infection and progression of cervical intraepithelial neoplasia: analysis of HLA polymorphism and HPV 16 E6 sequences variants. Int. J. Cancer 78, 166-171
  8. Bontkes, H.J., T.D. deGruijl, J.M. Walboomers, J.T. Schiller, J. Dillner, T.J. Helmerhorst, R.H. Vereheijen, R.J. Scheper, and C.J. Meijer. 1999. Immune responses against human papillomavirus (HPV) type 16 virus-like particles in a cohort study of women with cervical intraepithelial neoplasia. II. Systemic but not local IgA responses correlate with clearance of HPV-16. J. Gen. Virol. 80, 409-417
  9. Bosch F., M.M. Manos, N. Munoz, M. Sherman, A.M. Jansen, J. Peto, M.H. Shiffman, V. Moreno, R. Kurman, and K.V. Shah. 1995. Prevalence of human HPV in cervical cancer: a worldwide perspective. J. Natl. Cancer Inst. 87, 796-802
  10. Breitburd F., R. Kirnbauer, N.L. Hubbert, B. Nonnenmacher, C. Trin-Dinh-Desmarquet, G. Orth, J.T. Schiller, and D.R. Lowy. 1995. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J. Virol. 69, 3959-3963
  11. Burd, E.M. 2003. Human papillomavirus and cervical cancer. Clin. Microbiol. Rev. 16, 1-17
  12. Burk, R.D., P. Kelly, J. Feldman, J. Bromberg, S.H. Vermund, J.A. Deltovitz, and S.H. Landesman. 1996. Declining presence of cervicovaginal human papilllomavirus infection with age is independent of other risk factors. Sex Transm. Dis. 23, 333-341 https://doi.org/10.1097/00007435-199607000-00013
  13. Calore, E.E., S.M.M. Pereira, and M.J. Cavaliere. 2001. Progression of cervical lesions in HIV-seropositive women: a cytological study. Diagn. Cytopathol. 24, 117-119
  14. Campo, M.S., G.J. Grindlay, B.W. O'Neil, L.M. Chandrachud, G.M. McGarvie, and W.F. Jarrett. 1993. Prophylactic and therapeutic vaccination against a mucosal papillomavirus. J. Gen. Virol. 74, 945-953.
  15. Christensen, N.D., J.W. Kreider, N.M. Cladel, and D.A. Galloway. 1990. Immunological cross-reactivity to laboratory-produced HPV-11 virions of polysera raised against bacterially derived fusion proteins and synthetic peptides of HPV-6b and HPV-16 capsid proteins. Virology 175, 1-9
  16. Chua, K.L. and A. Hjerpe. 1996. Persistence of human papillomavirus (HPV) infections preceding cervical carcinoma. Cancer 77, 121-127
  17. Cubie, H.A., A.L. Seagar, G.J. Beattie, S. Monaghan, and A.R.W. Williams. 2000. A longitudinal study if HPV detection and cervical pathology in HIV infected women. Sex Transm. Infect. 76, 257-261
  18. Da Silva D.M., G.L. Eiben, S.C. Fausch, M.T. Wakabayashi, M.P. Rudolf, M.P. Velders, and W.M. Kast. 2001. Cervical cancer vaccines: emerging concepts and developments. J. Cell Physiol. 186, 169-182
  19. Dupuy, C., D. Buzoni-Gatel, A. Touze, D. Bout, and P. Coursaget. 1999. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J. Virol. 73, 9063-9071
  20. Emeny, R.T., C.M. Wheeler, K.U. Jansen, W.C. Hunt, T.M. Fu, J.F. Smith, S. MacMullen, M.T. Esser, and X. Paliard. 2002. Priming of human papillomavirus type 11-specific humoral and cellular immune responses in college-aged women with a viruslike particle vaccine. J. Virol. 76, 7832-7842
  21. Evander, M., I.H. Frazer, E. Payne, Y.M. Qui, K. Hengst, and N.A. McMillan. 1997. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J. Virol. 71, 2449-2456
  22. Evans, T.G., W. Bonnez, R.C. Rose, S. Koenig, L. Demeter, J.A. Suzich, D. O'Brien, M. Campbell, W.I. White, J. Balsley, and R.C. Reichman. 2001. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J. Infect. Dis. 183, 1485-1493
  23. Favre, M. 1975. Structural polypeptides of rabbit, bovine, and human papillomaviruses. J. Virol. 15, 1239-1247
  24. Franco, E.L. 1995. Cancer causes revisited:human papillomavirus and cervical neoplasia. J. Natl. Cancer Inst. 87, 779-780
  25. Galloway, D.A. 2003. Papillomavirus vaccines in clinical trials. Lancet Infect. Dis. 3, 469-475
  26. Greenstone, H.L., J.D. Nieland, K.E. de Visser, M.L. De Bruijn, R. Kirnbauer, R.B. Roden, D.R. Lowy, W.M. Kast, and J.T. Schiller. 1998. Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl. Acad. Sci. USA 95, 1800- 1805
  27. Giroglu, T., L. Florin, F. Schäfer, R.E. Stre, and M. Sapp. 2001. Human papillomavirus infection requires cell surface heparin sulfate. J. Virol. 75, 1565-1570
  28. Harro, C.D., Y.-Y.S. Pang, R.B.S. Roden, A. Hildesheim, Z. Wang, J.M. Reynolds, T.C. Mast, R. Robinson, B.R. Murphy, R.A. Karron, J. Dillner, J.T. Schiller, and D.R. Lowy. 2001. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J. Natl. Cancer Inst. 93, 284-292
  29. Hines, J.F., S.J. Ghim, N.D. Christensen, J.W. Kreider, W.A. Barnes, R. Schlegel, and A.B. Jenson. 1994. Role of conformational epitopes expressed by human papillomavirus major capsid proteins in the serologic detection of infection and prophylactic vaccination. Gynecol. Oncol. 55, 13-20
  30. Ho, G.Y., R. Bierman, L. Beardsley, C.J. Chang, and Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N. Engl. J. Med. 338, 413-428
  31. Holowaty, P., A.B. Miller, and T.T. Rohan. 1999. Natural dysplasia of the uterine cervix. J. Natl. Cancer Inst. 91, 252-258
  32. Hummel, M., J.B. Hudson, and L.A. Laimins. 1992. Differentiation-induced and constitutive transcription of human papillomavirus type 31b in cell lines containing viral episomes. J. Virol. 66, 6070-6080
  33. Jacobs, M.V., P.J. Snijders, A.J. van den Brule, T.J. Helmerhorst, C.J. Meijer, and J.M. Walboomers. 1997. A general primermediated PCR enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J. Clin. Microbiol. 35, 791-795
  34. Jeon, S., B.L. Allen-Hoffman, and P.F. Lambert. 1995. Integration of human papillomavirus type 16 into the human genome correlates with a selective growth advantage of cells. J. Virol. 69, 2989-2997
  35. Jin, X.W., J. Cash, and A.W. Kennedy. 1999. Human papillomavirus typing and the reduction of cervical cancer risk. Cleveland Clin. J. Med. 66, 533-539
  36. Joyce, J.G., J.-S. Tung, C.T. Przysiecki, J.C. Cook, E.D. Lehman, J.A. Sands, K.U. Jansen, and P.M. Keller. 1999. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J. Biol. Chem. 274 5810-5822.
  37. Kleter, B., L.J. van Doorn, L. Schrauwen, A. Molijn, S. Sastrowijoto, J. TerSchegget, J. Lindeman, B. Ter Harmsel, M. Burger, and W. Quint. 1999. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J. Clin. Microbiol. 37, 2508-2517
  38. Kim, K.Y., L. Blatt, and M.W. Taylor. 2000. The effects of interferon on the expression of human papillomavirus oncogenes. J. Gen. Virol. 81, 695-700
  39. Kiviat, N.B. and L.A. Koutsky. 1993. Specific human papillomavirus types as the causal agents of most cervical intraepithelial neoplasia: implications for current views and treatment. J. Natl. Cancer Inst. 85, 934-935
  40. Koutsky, L.A., K.A. Ault, C.M. Wheeler, D.R. Brown, E. Barr, F.B. Alvarez, L.M. Chiacchierini, and K.U. Jansen. 2002. A controlled trial of a human papillomavirus type 16 vaccine. N. Engl. J. Med. 347, 1645-1651
  41. Lizard, G., M.-J. De´mares-Poulet, P. Roignot, and P. Gambert. 2001. In situ hybridization detection of single-copy human papillomavirus on isolated cells using a catalyzed signal amplification system:GenPoint™. Diagn. Cytopathol. 24, 112-116
  42. Liu, W.J., K.N. Zhao, F.G. Gao, G.R. Leggatt, G.J. Fernando, and I.H. Frazer. 2001. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy. Vaccine 20, 862-869
  43. Magnusson, P.K.E., P. Lichtenstein, and U.B. Gyllenstein. 2000. Heritability of cervical tumors. Int. J. Cancer 88, 698-701
  44. Meyers, C., M.G. Frattini, J.B. Hudson, and L.A. Laimins. 1992. Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science 257, 971-973
  45. Moscicki, A.B., J. Palefsky, G. Smith, S. Siboshski, and G. Schoolnik. 1993. Variability of human papillomavirus DNA testing in a longitudinal cohort of young women. Obstst. Gynecol. 82, 578-585
  46. Muller, M., J. Zhou, T.D. Reed, C. Rittmuller, A. Burger, J. Gabelsberger, J. Braspenning, and L. Gissmann. 1997. Chimeric papillomavirus- like particles. Virology 234, 93-111
  47. Murray, P.R., K.S. Rosenthal, G.S. Kobayashi, and M.A. Pfaller. 2002. Papovaviruses, p. 460. In Medical Microbiology. Mosby Press, London, United Kingdom
  48. Okamoto, A., C.D. Woodworth, K. Yen, J. Chun, S. Isonishi, T. Nikaido, T. Kiyokawa, H. Seo, Y. Kitahara, K. Ochiai, and T. Tanaka. 1999. Combination therapy with podophyllin and vidarabine for human papillomavirus positive cervical intraepithelial neoplasia. Oncol. Rep. 6, 269-276
  49. Orth, G. and Favre, M. 1985. Human papillomaviruses. Biochemical and biologic properties. Clin. Dermatol. 3, 27-42
  50. Papanicolaou, G.N. 1949. A survey of actualities and potentialities of exfoliative cytology in cancer diagnosis. Ann. Intern. Med. 31, 661-674
  51. Philips, D.H., and M. NiShé. 1993. Smoking-related DNA adducts in human cervical biopsies. IARC Sci. Publ. 124, 327-330
  52. Quint, W.G.V., G. Scholte, L.J. Van Doorn, B. Kleeter, P.H.M. Smits, and J. Lindeman. 2001. Comparative analysis of human papillomavirus infections in cervical scrapes and biopsy specimens by general SPF10 PCR and HPV genotyping. J. Pathol. 194, 51-58
  53. Roden, R.B., D.R. Lowy, and J.T. Schiller. 1997. Papillomavirus is resistant to dessication. J. Infect Dis. 176, 1076-1079
  54. Roden, R.B., W.H. Yutzy, R. Fallon, S. Inglis, D.R. Lowy, and J.T. Schiller. 2000. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes. Virology 270, 254-257
  55. Santin, A.D., P.L. Hermonat, A. Ravaggi, M. Chiriva-Internati, D. Zhan, S. Pecorelli, G.P. Parham, and M.J. Cannon. 1999. Induction of human papillomavirus-specific CD4(+) and CD8(+) lymphocytes by E7-pulsed autologous dendritic cells in patients with human papillomavirus type 16- and 18-positive cervical cancer. J. Virol. 73, 5402-5410
  56. Solomon, D., D. Davey, R. Kurman, A. Moriarity, D. Oconnor, M. Prey, S. Raab, M. Sherman, D. Wilbur, T. Wright, and N. Young. 2002. The 2001 Bethesda System. Terminology for reporting results of cervical cytology. JAMA 287, 2114-2119
  57. Syrjänen, K.J. 1996. Natural history of genital human papillomavirus infections, p.189-206. In C. Lacey (ed.), Papillomavirus reviews. Leeds University Press, Leeds, United Kingdom
  58. Suzich, J.A., S.J. Ghim, F.J. Palmer-Hill, W.I. White, J.K. Tamura, J.A. Bell, J.A. Newsome, A.B. Jenson, and R. Schlegel. 1995. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc. Natl. Acad. Sci. USA 92, 11553-11557
  59. Tomas, M., D. Pim, and L. Banks. 1999. The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene 18, 7690-7700
  60. Torrisi, A., A. Del Mistro, G.L. Onnis, F. Merlin, R. Bertorelle, D. Minucci and D. Colposcopy. 2000. Cytology and HPV testing in HIV-positive and HIV-negative women. Eur. J. Gynecol. Oncol. 21, 168-172
  61. Villa, L.L. 1997. Human papillomaviruses and cervical cancer. Adv. Cancer Res.71, 321-341
  62. Walboomers, J.M.M., M.V. Jacobs, M.M. Manos, F.X. Bosch, J.A. Kummer, K.V. Shah, P.J.F. Snijders, J. Peto, C.J.L. Meijer, and N. Munoz. 1999. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J. Pathol. 189, 12-19
  63. Yang, X., G. Jin, Y. Nakao, M. Rahimtula, M. Pater, and A. Pater. 1996. Malignant transformation of HPV-16 immortalized human endocervical cells by cigarette smoke condensate and characterization of multistage carcinogenesis. Int. J. Cancer 65, 338-344 https://doi.org/10.1002/(SICI)1097-0215(19960126)65:3<338::AID-IJC11>3.0.CO;2-6
  64. zur Hausen, H. 1999. Papillomaviruses in human cancers. Proc. Assoc. Am. Physicians 111, 581-587